InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Poly(dA:dT) | Oxidative stress induces MUC5AC expression through mitochondrial damage-depen... | 2023 | FASEB Bioadv. | Nishida Y. et al. | DOI: 10.1096/fba.2022-00081 |
2'3'-cGAMP | Manganese Mediates Its Antiviral Functions in a cGAS-STING Pathway Independen... | 2023 | Viruses | Sun S. et al. | DOI: 10.3390/v15030646 |
Poly(dA:dT) | Manganese Mediates Its Antiviral Functions in a cGAS-STING Pathway Independen... | 2023 | Viruses | Sun S. et al. | DOI: 10.3390/v15030646 |
Blasticidin | The origin of long-chain fatty acids required for de novo ether lipid/plasmal... | 2023 | J Lipid Res. | Chornyi S. et al. | DOI: 10.1016/j.jlr.2023.100364 |
Recombinant anti-PD-L1 antibodies (D265A) - InvivoFit™ | Tumor-targeted superantigens produce curative tumor immunity with induction o... | 2023 | J Transl Med. | Azulay M. et al. | DOI: 10.1186/s12967-023-04064-z |
Poly(dA:dT) | A potential anti-HIV-1 compound, Q308, inhibits HSV-2 infection and replicati... | 2023 | Biomed Pharmacother. | Zhang X. et al. | DOI: 10.1016/j.biopha.2023.114595 |
CFA | The lactate dehydrogenase (LDH) isoenzyme spectrum enables optimally controll... | 2023 | Sci Adv. | Chen X. et al. | DOI: 10.1126/sciadv.add9554 |
OVA peptides | The lactate dehydrogenase (LDH) isoenzyme spectrum enables optimally controll... | 2023 | Sci Adv. | Chen X. et al. | DOI: 10.1126/sciadv.add9554 |
IL12elasti (p40::p35) | Fusion peptide is superior to co-expressing subunits for arming oncolytic her... | 2023 | Commun Med (Lond). | Fukuhara H. et al. | DOI: 10.1038/s43856-023-00270-4 |
Anti-hIL-6 Neutralizing mAb | Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 s... | 2023 | J Mol Cell Cardiol. | Candellier A. et al. | DOI: 10.1016/j.yjmcc.2023.03.011 |
Poly(I:C) HMW | Type I interferon signaling in malignant blasts contributes to treatment effi... | 2023 | Cell Death Dis. | Holicek P. et al. | DOI: 10.1038/s41419-023-05728-w |
ODN 2216 - TLR9 ligand | Type I interferon signaling in malignant blasts contributes to treatment effi... | 2023 | Cell Death Dis. | Holicek P. et al. | DOI: 10.1038/s41419-023-05728-w |
B16-Blue™ ISG Cells | Epigenetic state determines the in vivo efficacy of STING agonist therapy. | 2023 | Nat Commun. | Falahat R. et al. | DOI: 10.1038/s41467-023-37217-1 |
B16-Blue™ ISG-KO-STING Cells | Epigenetic state determines the in vivo efficacy of STING agonist therapy. | 2023 | Nat Commun. | Falahat R. et al. | DOI: 10.1038/s41467-023-37217-1 |
Zeocin® | Epigenetic state determines the in vivo efficacy of STING agonist therapy. | 2023 | Nat Commun. | Falahat R. et al. | DOI: 10.1038/s41467-023-37217-1 |
Ionomycin | Multiple Immune Defects in Two Patients with Novel DOCK2 Mutations Result in ... | 2023 | J Clin Immunol. | Li W. et al. | DOI: 10.1007/s10875-023-01466-y |
PHA-P | Multiple Immune Defects in Two Patients with Novel DOCK2 Mutations Result in ... | 2023 | J Clin Immunol. | Li W. et al. | DOI: 10.1007/s10875-023-01466-y |
Zeocin® | A novel Reelin construct, R36, recovered behavioral deficits in the heterozyg... | 2023 | Eur J Neurosci. | Morrill N.K. et al. | DOI: 10.1111/ejn.15971 |
2'3'-cGAMP | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |
ISD | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |